Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.51 |
| ▸ | PRKCA | P17252 | 2/20 | 0.46 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.46 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.43 |
| ▸ | FABP3 | P05413 | 2/20 | 0.43 |
| ▸ | DGKA | P23743 | 1/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26134552 | 1.00 | SLC6A5 (0.51) | SLC6A5PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL625049 | 0.90 | SLC6A5 (0.56) | SLC6A5PRKCAPRKCEPRKCQPRKCD | |
| Bromide SCHEMBL29051255 | 0.89 | SLC6A5 (0.55) | SLC6A5PRKCAPRKCEPRKCQPRKCD | |
| Hydrochloric Acid SCHEMBL25269826 | 0.89 | SLC6A5 (0.55) | SLC6A5PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL3371269 | 0.86 | SLC6A5 (0.53) | SLC6A5PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL23925777 | 0.85 | SLC6A5 (0.55) | SLC6A5PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL22319402 | 0.84 | SLC6A5 (0.54) | SLC6A5PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL29449493 | 0.84 | SLC6A5 (0.54) | SLC6A5PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL5824303 | 0.83 | SLC6A5 (0.50) | SLC6A5PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL6740155 | 0.81 | SLC6A5 (0.51) | SLC6A5PRKCAPRKCEPRKCQPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9289488-B2 | Vaccine engineering | AC IMMUNE SA (CH) | 2016-03-22 | — | — | US | claimed |
| WO-2024150064-A1 | LIPID BINDING PROTEIN MOLECULE THERAPY | ABIONYX PHARMA SA (FR) | 2024-07-18 | — | — | WO | disclosed |
| EP-4322746-A1 | USE OF LIPID BINDING PROTEIN-BASED COMPLEXES IN ORGAN PRESERVATION SOLUTIONS | Abionyx Pharma SA (FR) | 2024-02-21 | — | — | EP | disclosed |
| WO-2023237927-A2 | METHODS FOR TREATING HYPERINFLAMMATORY CONDITIONS USING LIPID BINDING PROTEIN -BASED COMPLEXES | ABIONYX PHARMA SA (FR) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023237935-A2 | METHODS FOR TREATING ACUTE CONDITIONS USING LIPID BINDING PROTEIN-BASED COMPLEXES | ABIONYX PHARMA SA (FR) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023194798-A1 | METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID BINDING PROTEIN-BASED COMPLEXES | ABIONYX PHARMA SA (FR) | 2023-10-12 | — | — | WO | disclosed |
| EP-3668600-A1 | CARGOMERS | Abionyx Pharma SA (FR) | 2020-06-24 | — | — | EP | disclosed |
| EP-3668549-A1 | APOMERS | Abionyx Pharma SA (FR) | 2020-06-24 | — | — | EP | disclosed |
| EP-3527220-A1 | VACCINE ENGINEERING | AC Immune S.A. (CH) | 2019-08-21 | — | — | EP | disclosed |
| WO-2019030575-A1 | APOMERS | CERENIS THERAPEUTICS HOLDING (FR) | 2019-02-14 | — | — | WO | disclosed |
| WO-2019030574-A1 | CARGOMERS | CERENIS THERAPEUTICS HOLDING (FR) | 2019-02-14 | — | — | WO | disclosed |
| EP-2758071-B1 | VACCINE THERAPY | AC IMMUNE SA (CH) | 2018-11-28 | — | — | EP | disclosed |
| US-9289488-B2 | Vaccine engineering | AC IMMUNE SA (CH) | 2016-03-22 | — | — | US | disclosed |
| US-20140314837-A1 | Vaccine Therapy | AC IMMUNE SA (CH) | 2014-10-23 | — | — | US | disclosed |
| EP-2758071-A1 | VACCINE THERAPY | AC Immune S.A. (CH) | 2014-07-30 | — | — | EP | disclosed |
| US-20130287838-A1 | VACCINE ENGINEERING | AC IMMUNE S.A. (CH) | 2013-10-31 | — | — | US | disclosed |
| WO-2013044147-A1 | VACCINE THERAPY | AC IMMUNE S.A. (CH) | 2013-03-28 | — | — | WO | disclosed |